ARTIVA BIOTHERAPEUTICS INC (ARTV) Forecast, Price Target & Analyst Ratings

NASDAQ:ARTVUS04317A1079

Current stock price

5.01 USD
-0.15 (-2.91%)
At close:
5.1128 USD
+0.1 (+2.05%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARTIVA BIOTHERAPEUTICS INC (ARTV).

Forecast Snapshot

Consensus Price Target

Price Target
$17.34
+ 246.11% Upside

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.89
Revenue Estimate

ChartMill Buy Consensus

Rating
85.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$17.34
Upside
+ 246.11%
From current price of $5.01 to mean target of $17.34, Based on 12 analyst forecasts
Low
$10.10
Median
$18.36
High
$24.15

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

12 Wall Street analysts provided a forecast for the next 12 months for ARTV. The average price target is 17.34 USD. This implies a price increase of 246.11% is expected in the next year compared to the current price of 5.01.

Analyst Ratings & History

Current Analyst Ratings

ARTV Current Analyst RatingARTV Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

ARTV Historical Analyst RatingsARTV Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.00%
ARTV was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ARTV.
In the previous month the buy percentage consensus was at a similar level.
ARTV was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11NeedhamReiterate Buy -> Buy
2025-11-12HC Wainwright & Co.Maintains Buy -> Buy
2025-10-17NeedhamReiterate Buy -> Buy
2025-10-17WedbushMaintains Outperform -> Outperform
2025-05-15NeedhamMaintains Buy -> Buy
2025-04-08NeedhamReiterate Buy -> Buy
2025-03-26HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-25Cantor FitzgeraldMaintains Overweight -> Overweight
2025-03-25NeedhamReiterate Buy -> Buy
2025-03-25WedbushReiterate Outperform -> Outperform
2024-12-30HC Wainwright & Co.Initiate Buy
2024-11-13NeedhamReiterate Buy -> Buy
2024-08-30NeedhamReiterate Buy -> Buy
2024-08-13TD CowenInitiate Buy
2024-08-13Cantor FitzgeraldInitiate Overweight
2024-08-13NeedhamInitiate Buy
2024-08-13WedbushInitiate Outperform
2024-08-13JefferiesInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 30, 2026
Period
Q1 / 2026
EPS Estimate
-$0.89
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-7.19%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
2.00%
EPS (3 Months)
2.00%

Next Earnings Summary

ARTV is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.89 USD and the consensus revenue estimate is 0 USD.

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ARTV revenue by date.ARTV revenue by date.
4.931M
146.30%
33.492M
579.21%
251K
-99.25%

-100.00%
2.856M55.573M
1,845.83%
149.71M
169.39%
335.9M
124.37%
539.18M
60.52%
661.18M
22.63%
EBITDA
YoY % growth
ARTV ebitda by date.ARTV ebitda by date.
-58.671M
-10.65%
-28.405M
51.59%
-64.851M
-128.31%
N/A
-34.48%
N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
ARTV ebit by date.ARTV ebit by date.
-59.829M
-12.31%
-30.671M
48.74%
-67.282M
-119.37%
-92.776M
-33.48%
-101.41M
-12.92%
-121.291M
-19.60%
-150.343M
-23.95%
-153.072M
-1.82%
-106.929M
30.14%
70.89M
166.30%
253.47M
257.55%
459M
81.09%
Operating Margin
ARTV operating margin by date.ARTV operating margin by date.
-1,213.32%-91.58%-26,805.58%N/AN/AN/A-5,264.12%-275.44%-71.42%21.10%47.01%69.42%
EPS
YoY % growth
ARTV eps by date.ARTV eps by date.
N/AN/AN/A-3.47
35.88%
-3.41
1.76%
-2.07
39.34%
-3.16
-52.71%
-2.78
11.94%
-0.86
69.23%
N/AN/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28
EPS
Q2Q % growth
-0.89
-7.19%
-0.86
0.58%
-0.85
3.10%
-0.90
-6.49%
-0.83
7.25%
-0.70
19.22%
-0.73
14.59%
-0.78
12.61%
-0.84
-2.35%
-0.89
-27.01%
-0.93
-28.01%
Revenue
Q2Q % growth
N/AN/AN/AN/AN/AN/AN/A
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-23.848M
-7.56%
-25.628M
-12.35%
-27.043M
-18.11%
-28.441M
-29.68%
N/AN/AN/AN/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ARTV Yearly Revenue VS EstimatesARTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2028 2029 2030 2031 2032 2033 200M 400M 600M
ARTV Yearly EPS VS EstimatesARTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
2.91%
EPS Next 5 Year
11.89%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

ARTIVA BIOTHERAPEUTICS INC / ARTV Forecast FAQ

What is the average price target for ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

12 analysts have analysed ARTV and the average price target is 17.34 USD. This implies a price increase of 246.11% is expected in the next year compared to the current price of 5.01.

Can you provide the upcoming earnings date for ARTIVA BIOTHERAPEUTICS INC?

ARTIVA BIOTHERAPEUTICS INC (ARTV) will report earnings on 2026-03-30.

What are the consensus estimates for ARTV stock next earnings?

The consensus EPS estimate for the next earnings of ARTIVA BIOTHERAPEUTICS INC (ARTV) is -0.89 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for ARTIVA BIOTHERAPEUTICS INC stock?

The consensus rating for ARTIVA BIOTHERAPEUTICS INC (ARTV) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.